# A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Source: https://onco.cc/trials/nct06695845/  
OnCo record `nct06695845` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zanidatamab in oesophageal cancer and colorectal cancer, run by Jazz Pharmaceuticals, now recruiting.

## Summary

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors is a phase 2 interventional study registered as NCT06695845 by Jazz Pharmaceuticals, with 200 participants planned, started 2025-01-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanidatamab. Conditions listed: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06695845
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
- Sponsor: Jazz Pharmaceuticals
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06695845: https://clinicaltrials.gov/study/NCT06695845

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- companies: [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/)

---
JSON: https://onco.cc/api/v1/entities/nct06695845.json